Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immunotherapy for the Treatment of Lymphoma

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2020 Dec 28

PMID 33361336

Citations 11

Authors

Sattva S Neelapu

Sherry Adkins

Stephen M Ansell

Joshua Brody

Mitchell S Cairo

Jonathan W Friedberg

Justin P Kline

Ronald Levy

David L Porter

Koen Van Besien

Michael Werner

Michael R Bishop

Affiliations

Soon will be listed here.

Abstract

The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.

Citing Articles

STAT3 Expression and Its Correlation with PD-L1 Expression in Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma at Dr. Saiful Anwar Regional Public Hospital in Malang, Indonesian Population.

Hambalie A, Norahmawati E, Endharti A, Retnani D, Rahmadiani N Adv Hematol. 2024; 2024:7989996.

PMID: 38817669 PMC: 11139532. DOI: 10.1155/2024/7989996.

Editorial: Diagnosis and therapy pediatric hematological malignancies: recent progress.

Zawitkowska J, Lejman M, Derwich K Front Pediatr. 2023; 11:1303561.

PMID: 37964814 PMC: 10640978. DOI: 10.3389/fped.2023.1303561.

Complement system in Anti-CD20 mAb therapy for cancer: A mini-review.

Gao Y Int J Immunopathol Pharmacol. 2023; 37:3946320231181464.

PMID: 37357623 PMC: 10331094. DOI: 10.1177/03946320231181464.

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma.

Wang Y, Zhang X, Xu C, Nan Y, Fan J, Zeng X Front Immunol. 2022; 13:1004475.

PMID: 36544785 PMC: 9762552. DOI: 10.3389/fimmu.2022.1004475.

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition).

Chen S, Zhao W, Li J, Wu D Front Med. 2022; 16(5):815-826.

PMID: 36152123 PMC: 9510206. DOI: 10.1007/s11684-021-0891-0.

References

Boyiadzis M, Bishop M, Abonour R, Anderson K, Ansell S, Avigan D . The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. PMC: 5168808. DOI: 10.1186/s40425-016-0188-z. View

Connors J . State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol. 2005; 23(26):6400-8. DOI: 10.1200/JCO.2005.05.016. View

Kim Y, Bagot M, Pinter-Brown L, Rook A, Porcu P, Horwitz S . Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19(9):1192-1204. DOI: 10.1016/S1470-2045(18)30379-6. View

Lin J, Muffly L, Spinner M, Barnes J, Owens D, Goldhaber-Fiebert J . Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. J Clin Oncol. 2019; 37(24):2105-2119. DOI: 10.1200/JCO.18.02079. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Gopal A, Chen R, Smith S, Ansell S, Rosenblatt J, Savage K . Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2014; 125(8):1236-43. PMC: 4335079. DOI: 10.1182/blood-2014-08-595801. View

Leonardi G, Gainor J, Altan M, Kravets S, Dahlberg S, Gedmintas L . Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol. 2018; 36(19):1905-1912. PMC: 6553840. DOI: 10.1200/JCO.2017.77.0305. View

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani P . Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018; 36(14):1428-1439. PMC: 6075855. DOI: 10.1200/JCO.2017.76.0793. View

Witzig T, Zinzani P, Habermann T, Tuscano J, Drach J, Ramchandren R . Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. Am J Hematol. 2017; 92(10):E575-E583. PMC: 6896320. DOI: 10.1002/ajh.24854. View

10.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

11.

Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O . Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015; 372(10):944-53. DOI: 10.1056/NEJMoa1412096. View

12.

Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K . Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2016; 58(5):1084-1093. DOI: 10.1080/10428194.2016.1233536. View

13.

Chen Q, Jain N, Ayer T, Wierda W, Flowers C, OBrien S . Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol. 2016; 35(2):166-174. PMC: 5559889. DOI: 10.1200/JCO.2016.68.2856. View

14.

Lee M, Chiou T, Hsiao L, Yang M, Lin P, Poh S . Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol. 2007; 87(4):285-9. DOI: 10.1007/s00277-007-0397-0. View

15.

Canellos G, Niedzwiecki D . Long-term follow-up of Hodgkin's disease trial. N Engl J Med. 2002; 346(18):1417-8. DOI: 10.1056/NEJM200205023461821. View

16.

Fischer K, Bahlo J, Fink A, Goede V, Herling C, Cramer P . Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2015; 127(2):208-15. DOI: 10.1182/blood-2015-06-651125. View

17.

Swinnen L, Mullen G, Carr T, Costanzo M, Fisher R . Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995; 86(9):3333-40. View

18.

Tao Q, Young L, Woodman C, Murray P . Epstein-Barr virus (EBV) and its associated human cancers--genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci. 2006; 11:2672-713. DOI: 10.2741/2000. View

19.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

20.

Maus M, Haas A, Beatty G, Albelda S, Levine B, Liu X . T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2014; 1(1):26-31. PMC: 3888798. DOI: 10.1158/2326-6066.CIR-13-0006. View